I have an exit strategy - nothing new or concealed there. When, how, and under what circumstances I decide to buy, hold, or sell are one's and one's alone. Directing one to do any of the above is not prudent and could carry consequences if taken to the extreme. However what I find alarming is the attitude expressed when any negativity is discussed regarding this security. It should stand to reason that in order to have a healthy investment approach, both sides of the story needed to be looked at and conveyed, just not one - and that goes for both all negative circumstances as well as all positive attributes of a public security. Some of us longs are tiring of the serial dilution we've experienced with AMBS and have every right to express that concern. If this security were to address this concern head-on and provide sustainable revenue which I believe it can do, IMHO, then all else will fall into place. If it does not and decides to go LymPro alone, then the 2nd 1-Bil. may prove to weigh too heavily on the pps and its diminishing returns effect will continue to be errosive on ones holdings and the pps. As we all know, one of the ways around this are to continue buying more as the company dilutes more. However, even some longs have time frames to deal with. May 2105 truly be AMBS's break out year and elimination of toxic death spiral financing and diminishing returns style dilution.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links